PMA

P100017: ABBOTT REALTIME HCV, ABBOTT REALTIME HCV AMPLIFICATION REAGENT KIT, ABBOTT REALTIME HVC CONTROL KIT, ABBOTT REALTIME HCV

FDA PMA · Assay, hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus · Abbott Molecular, Inc.

Key facts

PMA number P100017
Trade name ABBOTT REALTIME HCV, ABBOTT REALTIME HCV AMPLIFICATION REAGENT KIT, ABBOTT REALTIME HVC CONTROL KIT, ABBOTT REALTIME HCV
Generic name Assay, hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus
Applicant Abbott Molecular, Inc.
Owner/operator ABBOTT LABORATORIES
Product code MZP
Approval date May 17, 2011
Docket number 11M-0349
Notice date May 20, 2011
Establishment registration 3005248192
FEI number 3005248192

At a glance

  • 10–99 Supplements
  • Mar 5, 2021 Latest supplement decision
  • No Withdrawn
  • Yes Summary of safety and effectiveness on file
  • 10–99 UDI device identifiers (GUDID)
  • None MAUDE adverse event reports
  • None Recall events

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMA approvals

Premarket approval (PMA) is the FDA's most stringent review pathway, required for most Class III devices that support or sustain life or present a potentially unreasonable risk.

Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date:

Browse all PMA approvals